The Zydus Research Centre is the dedicated research arm of the Rs. 1900 crore Zydus Group. With its team of over 300 research professionals, ZRC spearheads the group’s quest of creating healthier and happier communities globally. Spread over an area of over 3,60,000 sq ft, ZRC is working on cutting edge technologies in 14 different scientific disciplines.

ZRC is equipped to carry out research in the areas of new drug discovery, novel biologics and NDDS. The centre is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The research scientists conduct seminal research in diverse disciplines including Medicinal Chemistry, Biotechnology, Bio-Informatics, Genomics, Molecular & Cellular Biology, Pharmacology & Toxicology, Microbiology, Analytical Research, CMC Research, Clinical Research, and Novel Drug Delivery Research.

Zydus Research Centre has also entered into collaborative research agreements with  Prolong Pharmaceuticals Inc., a US-based, venture-backed drug delivery research and development company and Karo Bio of Sweden, a drug discovery and development company specialising in nuclear receptors.  In collaboration with Prolong Pharmaceuticals Inc, ZRC is engaged in a drug discovery and development process for a next generation therapeutic protein, ‘PEG-EPO’, to treat severe anemia. In a three year strategic collaboration with Karo Bio, ZRC will address an unmet healthcare need by developing a novel, selective glucocorticoid receptor (GR) modulators for the treatment of inflammatory diseases.

ZRC’s research pipeline

• The NME - ZYH1, for treating dyslipidemia has successfully passed Phase I clinical trials, and is now in Phase II clinical trials

• ZYH2, the novel agent for treating diabetes is undergoing Phase I trials

• ZYI1, the anti-inflammatory and pain management compound has also successfully completed Phase I clinical trials and is now in Phase II clinical trials

• ZYO1, a novel drug candidate for treating obesity and related disorders, has completed Phase I clinical trials

• ZYH7, a novel drug candidate for treating dyslipidemia and metabolic disorders is in Phase 1 clinical trials

With an aim to be a research-based pharmaceutical company by 2020, Zydus Cadila  invests more than 8% of its turnover on research annually. A fully integrated, global healthcare provider, Zydus Cadila has strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to cosmeceuticals.

Website: www.zyduscadila.com/research